Followers | 901 |
Posts | 148899 |
Boards Moderated | 0 |
Alias Born | 08/13/2010 |
Friday, June 24, 2016 11:38:04 AM
Create – Discover – Deliver
Using a combinatorial rational design process and proprietary yeast strains and strain engineering technology for production of terpenoids, Amyris scientists build libraries of microorganisms that produce natural and novel compounds of pharmaceutical relevance. These compounds were previously difficult or impossible to obtain through traditional chemical synthesis.
These libraries can be generated in strains engineered to allow detection or selection of ligands with affinity to defined pharmaceutical targets. Once yeast strains with lead compounds are identified, the same combination of heterologous genes can be transferred into a yeast host optimized for terpenoid production at pilot or commercial scales.
Benefits
Nearly half of all drugs approved since 1994 are based on compounds present in natural products.
Many pharmaceutical companies have reduced or eliminated natural product drug discovery screening due to difficulties in access, complexities of natural product chemistry and purification, and challenges in supply.
There are over 30,000 known terpenoids in nature, and many terpenoid and terpene-derived molecules are biologically active signaling agents.
Amyris has developed a state-of-the-art platform for generating and screening diversity based on over a decade of experience in producing terpenoids.
Using combinatorial design, Amyris can produce more than 100,000 novel terpenoids derived from natural terpene scaffolds."
https://amyris.com/collaborations/%CE%BCpharm/
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent AMRSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:39 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/10/2024 02:24:29 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/10/2024 02:14:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:42:49 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/14/2023 09:34:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 10:23:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:43:26 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM